FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765403114> ?p ?o ?g. }

• W2765403114 endingPage "52" @default.
• W2765403114 startingPage "45" @default.
• W2765403114 abstract "To assess the cost-effectiveness of interleukin (IL)-17A inhibitor secukinumab vs the currently licensed biologic therapies in ankylosing spondylitis (AS) patients from a Canadian healthcare system perspective.A decision analytic model (semi-Markov) evaluated the cost-effectiveness of secukinumab 150 mg compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab biosimilar in a biologic-naïve population, over 60 years of time horizon (lifetime). The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50) response rate was used to assess treatment response at week 12. Non-responders or patients discontinuing initial-line of biologic therapy were allowed to switch to subsequent-line biologics. Model input parameters (short-term and long-term changes in BASDAI and Bath Ankylosing Spondylitis Functional Index [BASFI], withdrawal rates, adverse events, costs, resource use, utilities, and disutilities) were obtained from clinical trials, published literature, and other Canadian sources. Benefits were expressed as quality-adjusted life years (QALYs). Cost and benefits were discounted with an annual discount rate of 1.5% for all treatments.In the biologic-naïve population, secukinumab 150 mg dominated all comparators, as patients treated with secukinumab 150 mg achieved the highest QALYs (16.46) at the lowest cost (CAD 533,010) over a lifetime horizon vs comparators. In the deterministic sensitivity analysis, results were most sensitive to changes in baseline BASFI non-responders, BASDAI 50 at 3 months and discount rates. Probabilistic sensitivity analysis showed that secukinumab 150 mg demonstrated higher probability of achieving maximum net monetary benefit vs all comparators at various cost thresholds.This analysis demonstrates that secukinumab 150 mg is the most cost-effective treatment option for biologic-naïve AS patients compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab biosimilar for a lifetime horizon in Canada. Treatment with secukinumab translates into substantial benefits for patients and the healthcare system." @default.
• W2765403114 created "2017-11-10" @default.
• W2765403114 creator A5012043621 @default.
• W2765403114 creator A5032453977 @default.
• W2765403114 creator A5065898211 @default.
• W2765403114 creator A5073254211 @default.
• W2765403114 creator A5084523108 @default.
• W2765403114 date "2018-11-13" @default.
• W2765403114 modified "2023-10-18" @default.
• W2765403114 title "Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective" @default.
• W2765403114 cites W2016306307 @default.
• W2765403114 cites W2099909375 @default.
• W2765403114 cites W2102829569 @default.
• W2765403114 cites W2102994864 @default.
• W2765403114 cites W2135779150 @default.
• W2765403114 cites W2166444828 @default.
• W2765403114 cites W2270992578 @default.
• W2765403114 cites W2278932593 @default.
• W2765403114 cites W2302209142 @default.
• W2765403114 cites W2474733473 @default.
• W2765403114 cites W2510779786 @default.
• W2765403114 cites W2544823350 @default.
• W2765403114 cites W2555692533 @default.
• W2765403114 cites W2572897530 @default.
• W2765403114 cites W2750838249 @default.
• W2765403114 cites W2765169245 @default.
• W2765403114 cites W2765941038 @default.
• W2765403114 cites W2766459078 @default.
• W2765403114 cites W2769953079 @default.
• W2765403114 cites W2885214565 @default.
• W2765403114 cites W3129801150 @default.
• W2765403114 cites W4211203343 @default.
• W2765403114 doi "https://doi.org/10.1080/13696998.2018.1539400" @default.
• W2765403114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30346844" @default.
• W2765403114 hasPublicationYear "2018" @default.
• W2765403114 type Work @default.
• W2765403114 sameAs 2765403114 @default.
• W2765403114 citedByCount "11" @default.
• W2765403114 countsByYear W27654031142019 @default.
• W2765403114 countsByYear W27654031142020 @default.
• W2765403114 countsByYear W27654031142021 @default.
• W2765403114 countsByYear W27654031142023 @default.
• W2765403114 crossrefType "journal-article" @default.
• W2765403114 hasAuthorship W2765403114A5012043621 @default.
• W2765403114 hasAuthorship W2765403114A5032453977 @default.
• W2765403114 hasAuthorship W2765403114A5065898211 @default.
• W2765403114 hasAuthorship W2765403114A5073254211 @default.
• W2765403114 hasAuthorship W2765403114A5084523108 @default.
• W2765403114 hasBestOaLocation W27654031141 @default.
• W2765403114 hasConcept C112930515 @default.
• W2765403114 hasConcept C126322002 @default.
• W2765403114 hasConcept C17991360 @default.
• W2765403114 hasConcept C2776215756 @default.
• W2765403114 hasConcept C2776260265 @default.
• W2765403114 hasConcept C2777138892 @default.
• W2765403114 hasConcept C2777226972 @default.
• W2765403114 hasConcept C2777402515 @default.
• W2765403114 hasConcept C2777453003 @default.
• W2765403114 hasConcept C2778715236 @default.
• W2765403114 hasConcept C2779134260 @default.
• W2765403114 hasConcept C2779786854 @default.
• W2765403114 hasConcept C2780132546 @default.
• W2765403114 hasConcept C2780415856 @default.
• W2765403114 hasConcept C2781290027 @default.
• W2765403114 hasConcept C2908647359 @default.
• W2765403114 hasConcept C3019080777 @default.
• W2765403114 hasConcept C71924100 @default.
• W2765403114 hasConcept C99454951 @default.
• W2765403114 hasConceptScore W2765403114C112930515 @default.
• W2765403114 hasConceptScore W2765403114C126322002 @default.
• W2765403114 hasConceptScore W2765403114C17991360 @default.
• W2765403114 hasConceptScore W2765403114C2776215756 @default.
• W2765403114 hasConceptScore W2765403114C2776260265 @default.
• W2765403114 hasConceptScore W2765403114C2777138892 @default.
• W2765403114 hasConceptScore W2765403114C2777226972 @default.
• W2765403114 hasConceptScore W2765403114C2777402515 @default.
• W2765403114 hasConceptScore W2765403114C2777453003 @default.
• W2765403114 hasConceptScore W2765403114C2778715236 @default.
• W2765403114 hasConceptScore W2765403114C2779134260 @default.
• W2765403114 hasConceptScore W2765403114C2779786854 @default.
• W2765403114 hasConceptScore W2765403114C2780132546 @default.
• W2765403114 hasConceptScore W2765403114C2780415856 @default.
• W2765403114 hasConceptScore W2765403114C2781290027 @default.
• W2765403114 hasConceptScore W2765403114C2908647359 @default.
• W2765403114 hasConceptScore W2765403114C3019080777 @default.
• W2765403114 hasConceptScore W2765403114C71924100 @default.
• W2765403114 hasConceptScore W2765403114C99454951 @default.
• W2765403114 hasIssue "1" @default.
• W2765403114 hasLocation W27654031141 @default.
• W2765403114 hasLocation W27654031142 @default.
• W2765403114 hasOpenAccess W2765403114 @default.
• W2765403114 hasPrimaryLocation W27654031141 @default.
• W2765403114 hasRelatedWork W2270992578 @default.
• W2765403114 hasRelatedWork W2411669382 @default.
• W2765403114 hasRelatedWork W2539904812 @default.
• W2765403114 hasRelatedWork W2765169245 @default.
• W2765403114 hasRelatedWork W2765403114 @default.
• W2765403114 hasRelatedWork W2912302362 @default.

• next